Frontier Biotechnologies688221.SHValuation Analysis

As of Oct 19, 2026, Frontier Biotechnologies (688221.SH) trades at a negative P/E (-236.06x, due to a recent net loss), P/B of 4.98x, P/S of 8.20x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 74th percentile over the trailing 10Y window (vs. 55th percentile over 3Y); P/S sits at the 9th percentile over the trailing 10Y window (vs. 17th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 84th percentile within its industry and the 81st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Frontier Biotechnologies operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.